伊朗艾滋病毒感染者中的丙型肝炎病毒流行率:系统回顾与荟萃分析

Q3 Medicine
Maedeh Hajizadeh , Maryam Moradi Binabaj , Arezoo Asadi , Milad Abdi , Abolfazl Shakiba , Masoumeh Beig , Mohsen Heidary , Mohammad Sholeh
{"title":"伊朗艾滋病毒感染者中的丙型肝炎病毒流行率:系统回顾与荟萃分析","authors":"Maedeh Hajizadeh ,&nbsp;Maryam Moradi Binabaj ,&nbsp;Arezoo Asadi ,&nbsp;Milad Abdi ,&nbsp;Abolfazl Shakiba ,&nbsp;Masoumeh Beig ,&nbsp;Mohsen Heidary ,&nbsp;Mohammad Sholeh","doi":"10.1016/j.vacun.2023.08.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major </span>public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.</p></div><div><h3>Methods</h3><p><span>MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV </span>treatment. The analysis was carried out using R and the metafor package.</p></div><div><h3>Results</h3><p>We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).</p></div><div><h3>Conclusion</h3><p><span>HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further </span>epidemiologic studies are necessary.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis\",\"authors\":\"Maedeh Hajizadeh ,&nbsp;Maryam Moradi Binabaj ,&nbsp;Arezoo Asadi ,&nbsp;Milad Abdi ,&nbsp;Abolfazl Shakiba ,&nbsp;Masoumeh Beig ,&nbsp;Mohsen Heidary ,&nbsp;Mohammad Sholeh\",\"doi\":\"10.1016/j.vacun.2023.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major </span>public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.</p></div><div><h3>Methods</h3><p><span>MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV </span>treatment. The analysis was carried out using R and the metafor package.</p></div><div><h3>Results</h3><p>We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).</p></div><div><h3>Conclusion</h3><p><span>HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further </span>epidemiologic studies are necessary.</p></div>\",\"PeriodicalId\":53407,\"journal\":{\"name\":\"Vacunas\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vacunas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1576988723000687\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988723000687","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)感染是全球主要的公共卫生问题。本研究旨在估算伊朗 HIV 感染者中的 HCV 感染率,并评估与结果异质性相关的人口和行为因素。方法:系统检索了 2005 年 1 月 1 日至 2022 年 2 月 26 日期间的 MedLINE(通过 PubMed)、Web of Science、SCOPUS、Google Scholar、Embase 和 2 个波斯语数据库,包括科学信息数据库 (SID) 和 Magiran。根据国家、发表时间、入选时间、患者人数、性别、平均年龄、HIV/HCV 诊断方法和 HIV/HCV 治疗方法对数据进行了分析。结果我们发现,伊朗有 60.94(95% CI 54.59-67.11)名 HIV 感染者合并感染了 HCV。哈马丹86.67 (62.12, 96.26)、卡尚85.71 (75.03, 92.30)和克尔曼73.94 (66.75, 80.04)的合并感染率最高。结论 HBV-HCV 合并感染是一种具有挑战性的重要病症,因为其临床表现多变,肝硬化和 HCC 风险增加,治疗反应难以预测。由于 HBV-HCV 感染在伊朗的分布模式各不相同,因此有必要采取持续的预防和控制措施,并开展进一步的流行病学研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis

Background

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.

Methods

MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV treatment. The analysis was carried out using R and the metafor package.

Results

We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).

Conclusion

HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further epidemiologic studies are necessary.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vacunas
Vacunas Medicine-Infectious Diseases
CiteScore
3.90
自引率
0.00%
发文量
138
审稿时长
62 days
期刊介绍: Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信